Selene Therapeutics Ltd. has identified brain permeable dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of epilepsy, cancer, Alzheimer’s disease, rheumatoid arthritis and multiple sclerosis.

Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of cardiotoxicity.

The Scripps Research Institute has disclosed κ-opioid receptor antagonists reported to be useful for the treatment of depression, anxiety, schizophrenia, obesity, migraine, substance abuse and dependence, epilepsy and eating disorders, among others.

Qingdao Putaike Biomedical Technology Co. Ltd. has described androgen receptor full length (AR-FL) and/or androgen receptor variant 7 (AR-v7) degradation inducers reported to be useful for the treatment of acne vulgaris, androgenic alopecia, cancer, hirsutism, metabolic diseases, polycystic ovary syndrome, precocious puberty and benign prostatic hyperplasia, among others.

Schroedinger Inc. has divulged Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, autoimmune disorders, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.

Shanghai Henlius Biologics Co. Ltd. has synthesized histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.

Xi’an Xintong Medicine Research Co. Ltd. has disclosed thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, thyroid cancer, diabetes, obesity and hypothyroidism.

Lucy Therapeutics Inc. has described adenosine receptor agonists reported to be useful for the treatment of Rett syndrome and chronic heart failure.

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting moiety reported to be useful for the treatment of arthritis, Behçet’s disease, chronic obstructive pulmonary disease, non-small-cell lung cancer, inflammatory disorders, inflammatory bowel disease, psoriasis and rheumatoid arthritis.